Savara, Inc., an inhalation drug delivery company, today announced that it has been chosen by the state of Texas as the recipient of a commercialization award funded through the Texas Emerging Technology Fund (ETF). The company, which produces novel respiratory therapeutics, will receive a $1.9 million award for the commercialization of its products. “Savara’s dry-powder technology holds great potential for treating asthma, lung cancer, and other lung-based diseases,” said Jack McDonald Chairman of Perficient, Inc. [...]